FDA's 'first oral drug' claim for dermatomyositis needs a footnote

The FDA approved Lisraya (brepocitinib) on August 27 as the first oral drug for dermatomyositis, an inflammatory disease that attacks skin and muscle. Healio's writeup of the agency's press release captures the headline claim cleanly, but the phrase "first oral drug" is doing more work than a quick read suggests, and the underlying trial data published in two journals within a day of the approval reward a closer look at what was actually measured, when, and by whom.

Start with the framing itself. Dermatomyositis already had one FDA-approved treatment before Lisraya: Octapharma's intravenous immunoglobulin product Octagam 10%, cleared in July 2021 on the strength of the ProDERM trial. Lisraya is the first oral therapy for the disease, not the first approved therapy of any kind. Before 2021, dermatomyositis patients were treated entirely with drugs approved for other conditions: corticosteroids, methotrexate, mycophenolate, sometimes tofacitinib off-label. The Myositis Association's statement on the approval leans on that history, calling Lisraya the first treatment designed for myositis rather than borrowed from another disease, a claim that holds even though the drug itself is not the category's first approval.

The clinical evidence behind the decision comes from VALOR, a 52-week, placebo-controlled Phase 3 trial of 241 patients across 90 sites, published in the New England Journal of Medicine. Patients on the 30 mg dose reached a Total Improvement Score of 46.5 at week 52 versus 31.2 on placebo, a difference reported as statistically significant, with separation visible from week 4 onward. That is a well-powered result, and the trial is described as the first positive 52-week placebo-controlled study run in this disease. What the NEJM paper does not establish is how brepocitinib performs against other targeted options, because VALOR carried no active comparator arm. A trial built against placebo can show that a drug works better than nothing; it cannot show that it works better than an alternative nobody tested against it.

A second dataset arrived one day before the FDA's announcement: a JAMA Dermatology paper reporting the trial's skin-specific outcomes, timed to land alongside the approval news rather than months apart. Publishing the skin data separately, and just ahead of the regulatory decision, is a common industry practice for building a coordinated media moment, but it also means the full picture of the drug's effect sits across two papers rather than one, and a reader relying on either alone gets a partial view: the muscle and overall disease activity data in NEJM, the skin activity data in JAMA Dermatology.

The safety label is where the trial's scope matters most. Lisraya carries the boxed warning now standard across JAK-inhibitor class drugs: serious infections, increased all-cause mortality, malignancy, major cardiovascular events, and thrombosis. That warning originated with tofacitinib's ORAL Surveillance trial, a study conducted in older rheumatoid arthritis patients with existing cardiovascular risk factors, a population that does not resemble the younger, often-female dermatomyositis patients now receiving Lisraya. Within VALOR itself, discontinuation for adverse events was actually lower on the drug (6%) than on placebo (11%), and the trial's few cancer and blood-clot events occurred exclusively in the placebo group. That is reassuring within the confines of a 52-week study, but a single trial of 241 patients is not statistically equipped to rule out rare, serious risks the way the boxed warning implies exist. The label reflects a class-wide inference carried over from a different patient population, not a finding generated by VALOR itself.

None of this contradicts the approval or the trial's core finding, that a TYK2/JAK1 inhibitor outperformed placebo over a full year in a disease that has resisted rigorous testing for decades. It does mean the two most quotable claims in circulation this week, "first oral drug" and the boxed warning's risk profile, describe less than they appear to at first read: one compares Lisraya to a category it entered second, and the other imports a risk estimate from a trial population Lisraya's own patients don't match. The FDA's press release and Priovant's own materials treat both facts as settled; the underlying documents show them as narrower and more provisional than the headlines let on.